✦ LIBER ✦

The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: An unresolved controversy

✍ Scribed by Conteduca, Vincenza; Di Lorenzo, Giuseppe; Tartarone, Alfredo; Aieta, Michele

Book ID: 123435454
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 572 KB
Volume: 86
Category: Article
ISSN: 1040-8428
DOI: 10.1016/j.critrevonc.2012.09.008

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Gonadotropin-Releasing Hormone Agonists

Gonadotropin-Releasing Hormone Agonists and the Risks of Type 2 Diabetes and Cardiovascular Disease in Men with Prostate Cancer

✍ Dr Philip J. Saylor, Nancy L. Keating, Stephen J. Freedland, Matthew R. Smith 📂 Article 📅 2011 🏛 Springer International Publishing AG 🌐 English ⚖ 117 KB

Gonadotropin-releasing hormone agonist u

Gonadotropin-releasing hormone agonist use in men without a cancer registry diagnosis of prostate cancer

✍ Yong-fang Kuo; James S Goodwin; Vahakn B Shahinian 📂 Article 📅 2008 🏛 BioMed Central 🌐 English ⚖ 260 KB

Gonadotrophin-releasing hormone agonists

Gonadotrophin-releasing hormone agonists, diabetes and cardiovascular disease in men with prostate cancer: which metabolic syndrome?

✍ Matthew R. Smith; A. James O’Malley; Nancy L. Keating 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 87 KB

677 Lower risk of cardiovascular (CV) ev

677 Lower risk of cardiovascular (CV) events and death in men receiving ADT by gonadotropin releasing hormone (GnRH) antagonist, degarelix, compared with luteinising hormone-releasing (LHRH) agonists

✍ Tombal, B.; Albertsen, P.; De La Taille, A.; Van Der Meulen, E.; Persson, B-E.; 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 142 KB

Luteinizing hormone–releasing hormone ag

Luteinizing hormone–releasing hormone agonists in the treatment of men with prostate cancer: timing, alternatives, and the 1-year implant

✍ LEONARD S Marks 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 266 KB

AN IMPLANT RELEASING THE GONADOTROPIN HO

AN IMPLANT RELEASING THE GONADOTROPIN HORMONE-RELEASING HORMONE AGONIST HISTRELIN MAINTAINS MEDICAL CASTRATION FOR UP TO 30 MONTHS IN METASTATIC PROSTATE CANCER

✍ CHERTIN, BORIS; SPITZ, IRVING M.; LINDENBERG, TZINA; ALGUR, NURIT; ZER, TAMI; KU 📂 Article 📅 2000 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 94 KB